---
title: "Kiora Pharmaceuticals, Inc. (KPRX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/KPRX.US.md"
symbol: "KPRX.US"
name: "Kiora Pharmaceuticals, Inc."
industry: "制藥"
---

# Kiora Pharmaceuticals, Inc. (KPRX.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.kiorapharma.com](https://www.kiorapharma.com) |

## Company Profile

Kiora Pharmaceuticals, Inc.是一家臨床階段的專業制藥公司，專注于眼科疾病治療療法的開發和商業化。其主要產品 KIO-301 是一種潛在的視力恢复小分子，目前正在進行針對視網膜色素變性、脈絡膜萎縮和斯塔加特病的二期臨床試驗。該公司還在開發 KIO-104，這是一種非類固醇的免疫調節小分子二氫尿嘧啶脫氫酶抑制劑，目前正在進行針對后非感染性葡萄膜炎的 1b/2a 期研究，同時也在進行增殖性玻璃體視網膜病的臨床前開發；以及 KIO-101，一種用于治療類風濕關節炎眼部表現的眼藥水配方。該公司與 Théa Open Innovation 簽訂了 KIO-301 的戰略開發和商業...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:13.000Z

**Overall: D (0.76)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 164 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -253.92% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.33 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7.41M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -32.58% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -253.92% | E |
| Total Assets YoY | -22.45% | E |
| Net Assets YoY | -25.37% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 24.96% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Kiora Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-32.58%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-253.92%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.45%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-25.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "24.96%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 禮來 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 羅氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 諾華制藥 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.87 | 98/256 | 2.60 | 2.22 | 1.76 |
| PB | 0.33 | 14/256 | 0.40 | 0.37 | 0.33 |
| PS (TTM) | 359.18 | - | 433.75 | 359.18 | 0.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-11T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.09 |
| Highest Target | 12.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/KPRX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/KPRX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/KPRX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.